Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

James A Watson

University of Oxford

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

90%

Epidemiology

30%

Malaria Epidemiology

90%

Pharmacometrics

50%

Antiretroviral Therapy

40%

Drug Repurposing

40%

Disease Transmission

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles30

Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

Article Link

Year:

2025

Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.

Article Link

Year:

2025

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).

Article Link

Year:

2025

Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites

Article Link

Year:

2024

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'

Article Link

Year:

2024

The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis.

Article Link

Year:

2024

Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match.

Article Link

Year:

2024

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).

Article Link

Year:

2024

Spatial Analysis of Drug-Susceptible and Multidrug-Resistant Cases of Tuberculosis, Ho Chi Minh City, Vietnam, 2020-2023.

Article Link

Year:

2024

Where will rectal artesunate suppositories save lives?

Article Link

Year:

2024

Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.

Article Link

Year:

2024

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

Article Link

Year:

2024

Rectal artesunate: lives not saved

Article Link

Year:

2024

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Article Link

Year:

2024

Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis

Article Link

Year:

2024

Modeling the within-host dynamics of Plasmodium vivax hypnozoite activation: An analysis of the SPf66 vaccine trial

Article Link

Year:

2024

Advancing the chemotherapy of tuberculous meningitis: a consensus view.

Article Link

Year:

2024

Transmission-blocking activities of artesunate, chloroquine, and methylene blue on <i>Plasmodium vivax</i> gametocytes.

Article Link

Year:

2024

WHO should accelerate, not stall, rectal artesunate deployment for pre-referral treatment of severe malaria

Article Link

Year:

2023

Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV).

Article Link

Year:

2023

The CARAMAL study could not assess the effectiveness of rectal artesunate in treating suspected severe malaria.

Article Link

Year:

2023

Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis.

Article Link

Year:

2023

A global core outcome measurement set for snakebite clinical trials.

Article Link

Year:

2023

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV).

Article Link

Year:

2023

Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria.

Article Link

Year:

2023

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

Article Link

Year:

2023

Population heterogeneity in Plasmodium vivax relapse risk.

Article Link

Year:

2022

The clinical pharmacology of tafenoquine in the radical cure of <i>Plasmodium vivax</i> malaria: An individual patient data meta-analysis.

Article Link

Year:

2022

The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria.

Article Link

Year:

2022

Substantial misdiagnosis of severe malaria in African children.

Article Link

Year:

2022

Collaborators9

Marcus Vinicius Guimarães de Lacerda

Adjunct Professor

University of Texas Medical Branch

UNITED STATES

James A. Seddon

UNITED KINGDOM

Richard Price

University of Oxford

UNITED KINGDOM

Naomi Waithira

Head of Data Management

University of Oxford

UNITED KINGDOM

Roberto Amato

GlaxoSmithKline (United States)

UNITED KINGDOM

Thomas Peto

University of Oxford

UNITED KINGDOM

Nicholas White

University of Oxford

UNITED KINGDOM

Julie Simpson

University of Melbourne

AUSTRALIA

Arjun Chandna

NIHR Academic Clinical Lecturer

London School of Hygiene & Tropical Medicine

UNITED KINGDOM

How do I reach out?

Meet Kite AI